Tag Archives: solanezumab

Praying and Paying for Hope

The FDA’s approval of Sarepta Therapeutics’ eteplirsen for Duchenne Muscular Dystrophy (DMD) turned the spotlight on a decision process that has tapped fundamental fissures within the FDA and the scientific community, fractures that could reverberate in far larger scale in … Continue reading

Posted in Big Pharma, Biotech | Tagged , , | Leave a comment

mAbMEN: It’s Not Over

Eli Lilly: Experimental Alzheimer’s drug shows some benefit  (AP) Eli Lilly’s Solanezumab Is the Alzheimer’s Drug Equivalent of the Internet Dress                (TheStreet) Lilly says drug slows Alzheimer’s in patients with mild disease (Reuters) Lilly’s Alzheimer’s Drug May Slow Patients’ Decline … Continue reading

Posted in Big Pharma, BioFollies, Biotech, Science | Tagged , , , , | Leave a comment

Fear and Loathing in Las Vegas*: The Persistence of Gonzo Neuroscience

Like a chronic gambler who keeps thinking that the next time will turn out different, the pharma industry has developed a nasty habit of sidling back to the Alzheimer’s roulette table, putting all their chips on 7, and watching forlornly … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , | Leave a comment

The Last Shoe Drops for Solanezumab

Just a tad too late for inclusion in the November issue of NeuroPerspective, the biomarker data for solanezumab were presented, at the CTAD meeting in Monte Carlo. As we had noted in a previous post (‘Chinese Data Torture’),  the data … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment

What A Long Strange Trip It’s Been: Solanezumab

Alzheimer’s is the major focus of the just-released September issue of NeuroPerspective, and we have already received a number of comments and questions. One of the big questions is –what will come next for solanezumab? This presumes that the release … Continue reading

Posted in Uncategorized | Tagged , , | Leave a comment

A Silver Lining to Sola?

The headlines for the Phase III topline results for Lilly‘s solanezumab were pretty much the same as for bapineuzemab: Primary endpoints were missed, and by that definition, the Phase III program was a failure. But there was a very ambiguous … Continue reading

Posted in Uncategorized | Tagged , , , , | Leave a comment